首页> 中文期刊> 《癌症》 >SHMTI C1420T polymorphism contributes to the risk of non-Hodgkin lymphoma: evidence from 7309 patients

SHMTI C1420T polymorphism contributes to the risk of non-Hodgkin lymphoma: evidence from 7309 patients

         

摘要

Background Serine hydroxymethyltransferase 1 (SHMT1) is a key enzyme in the folate metabolic pathway thatplays an important role in biosynthesis by providing one carbon unit. SHMT1 C1420T may lead to the abnormalbiosynthesis involved in DNA synthesis and methylation, and it may eventually increase cancer susceptibility. Manyepidemiologic studies have explored the association between C1420T polymorphism and the risk of non-Hodgkinlymphoma (NHL), but the results have been contradictory.Therefore, we performed this meta-analysis to evaluate therelationship.Methods: The meta-analyses were conducted to evaluate the effect of SHMT1 C1420T polymorphism on NHL risk.Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to measure the strength of the association.Results: Eight studies encompassing 3232 cases and 4077 controls were included. A statistically significant associationwas found between SHMT1 C1420T polymorphism and NHL risk under the allelic comparison (T vs. C: OR = 1.09,95% Cl 1.01-1.17); a borderline association was found between SHMT1 C1420T polymorphism and NHL risk under thehomozygote model (TT vs. CC: OR = 1.18,95% Cl 1.00-1.39) and the dominant model (CT+TT vs. CC: OR = 1.10,95%Ci 1.00-1.21).Conclusion: SHMT1 C1420T polymorphism may be associated with NHL risk, which needs to be validated in large,prospective studies.

著录项

相似文献

  • 中文文献
  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号